ID   KP-MRT-NS
AC   CVCL_7050
SY   Kyoto Pediatrics-Malignant Rhabdoid Tumor-NS
DR   Wikidata; Q54900382
RX   CelloPub=CLPUB00599;
RX   PubMed=9920784;
RX   PubMed=10417765;
RX   PubMed=15355927;
RX   PubMed=18281554;
RX   PubMed=21871868;
CC   Population: Japanese.
CC   Doubling time: 72 hours (PubMed=10417765).
CC   Karyotypic information: 46,XX,add(10)(q26) [17]; 46,XX,add(10)(q26),dic(1;2)(p22;q31) [3] (PubMed=10417765).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C8715; Rhabdoid tumor of the kidney
DI   ORDO; Orphanet_69077; Rhabdoid tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   11M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 13
//
RX   CelloPub=CLPUB00599;
RA   Sugimoto T., Kuroda H., Kuwahara Y., Katsumi Y., Misawa A.,
RA   Moritake H., Hosoi H.;
RT   "Cellular and molecular characteristics of established childhood
RT   soft-tissue sarcoma cell lines.";
RL   J. Cancer Res. Therap. Oncol. 7:202.1-202.12(2019).
//
RX   PubMed=9920784; DOI=10.1006/bbrc.1998.9968;
RA   Mori T., Fukuda Y., Kuroda H., Matsumura T., Ota S., Sugimoto T.,
RA   Nakamura Y., Inazawa J.;
RT   "Cloning and characterization of a novel Rab-family gene, Rab36,
RT   within the region at 22q11.2 that is homozygously deleted in malignant
RT   rhabdoid tumors.";
RL   Biochem. Biophys. Res. Commun. 254:594-600(1999).
//
RX   PubMed=10417765; DOI=10.1002/(SICI)1097-0215(19990827)82:5<678::AID-IJC10>3.0.CO;2-K;
RA   Sugimoto T., Hosoi H., Horii Y., Ishida H., Mine H., Takahashi K.,
RA   Abe T., Ohta S., Sawada T.;
RT   "Malignant rhabdoid-tumor cell line showing neural and smooth-muscle-cell
RT   phenotypes.";
RL   Int. J. Cancer 82:678-686(1999).
//
RX   PubMed=15355927; DOI=10.1158/1078-0432.CCR-04-0192;
RA   Kuwahara Y., Hosoi H., Osone S., Kita M., Iehara T., Kuroda H.,
RA   Sugimoto T.;
RT   "Antitumor activity of gefitinib in malignant rhabdoid tumor cells in
RT   vitro and in vivo.";
RL   Clin. Cancer Res. 10:5940-5948(2004).
//
RX   PubMed=18281554; DOI=10.1158/1078-0432.CCR-07-1661;
RA   Katsumi Y., Kuwahara Y., Tamura S., Kikuchi K., Otabe O., Tsuchiya K.,
RA   Iehara T., Kuroda H., Hosoi H., Sugimoto T.;
RT   "Trastuzumab activates allogeneic or autologous antibody-dependent
RT   cellular cytotoxicity against malignant rhabdoid tumor cells and
RT   interleukin-2 augments the cytotoxicity.";
RL   Clin. Cancer Res. 14:1192-1199(2008).
//
RX   PubMed=21871868; DOI=10.1016/j.bbrc.2011.08.047; PMCID=PMC3214763;
RA   Katsumi Y., Iehara T., Miyachi M., Yagyu S., Tsubai-Shimizu S.,
RA   Kikuchi K., Tamura S., Kuwahara Y., Tsuchiya K., Kuroda H.,
RA   Sugimoto T., Houghton P.J., Hosoi H.;
RT   "Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is
RT   inversely correlated with p16 expression.";
RL   Biochem. Biophys. Res. Commun. 413:62-68(2011).
//